SCHEMBL30856517

SCHEMBL30856517

C=CCOC(=O)[C@@H]1C[C@@H](O)CN1C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.39
▸ FABP5 Q01469 3/20 0.38
▸ FABP7 O15540 2/20 0.38
▸ KMT2A Q03164 3/20 0.37
▸ POLB P06746 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ EPHX2 P34913 1/20 0.35
▸ DPP8 Q6V1X1 1/20 0.34
▸ DPP9 Q86TI2 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ PRCP P42785 1/20 0.33
▸ TSHR P16473 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8247701 1.00 CYP19A1 (0.39) CYP19A1FABP5FABP7KMT2APOLB
SCHEMBL30170466 1.00 CYP19A1 (0.39) CYP19A1FABP5FABP7KMT2APOLB
SCHEMBL19371247 1.00 CYP19A1 (0.39) CYP19A1FABP5FABP7KMT2APOLB
SCHEMBL19391069 1.00 CYP19A1 (0.39) CYP19A1FABP5FABP7KMT2APOLB
SCHEMBL26008578 0.92 KMT2A (0.39) CYP19A1FABP5FABP7KMT2ANPSR1
SCHEMBL26008577 0.92 KMT2A (0.39) CYP19A1FABP5FABP7KMT2ANPSR1
SCHEMBL25817021 0.88 KMT2A (0.40) CYP19A1FABP5FABP7KMT2AEPHX2
SCHEMBL3789335 0.84 KMT2A (0.43) FABP5FABP7KMT2APOLBEPHX2
SCHEMBL3783542 0.84 KMT2A (0.43) FABP5FABP7KMT2APOLBEPHX2
SCHEMBL3793423 0.84 KMT2A (0.43) FABP5FABP7KMT2APOLBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317729-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-26 — — US disclosed
CN-117736134-A Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases 耶鲁大学 2024-03-22 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317729-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase MDM2, VHL, XIAP CYP19A1 3485/4885FABP5 1671/4885FABP7 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback